Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord-derived mesenchymal stem cell therapy for COVID-19 ARDS
IRCT20160809029275N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jun 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of allogeneic umbilical cord-derived mesenchymal stem cells in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Respiratory status and pulmonary disease in patients, Inflammatory cytokine levels and 1 more. Started Jun 2020; status: completed.
02
Drugs
allogeneic umbilical cord-derived mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on IRCT20160809029275N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160809029275N1.